The Board of Eliem Therapeutics, Inc. has approved a corporate reorganization plan to conserve financial resources. As part of the reorganization, the Company will reduce its workforce by approximately 55% in the first half of 2023. In connection with this reorganization, Bob Azelby, chief executive officer will be departing the Company and the Board imminently.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.065 USD | +7.15% | +1.62% | +225.56% |
Apr. 11 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Apr. 11 | Top Midday Gainers | MT |
1st Jan change | Capi. | |
---|---|---|
+221.85% | 237M | |
+5.26% | 109B | |
+11.35% | 105B | |
-0.03% | 22.25B | |
-12.18% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.93% | 16.85B | |
+4.83% | 13.76B | |
+35.31% | 12.46B |
- Stock Market
- Equities
- ELYM Stock
- News Eliem Therapeutics, Inc.
- Bob Azelby to Depart as Chief Executive Officer of Eliem Therapeutics, Inc